Cargando…

The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population

The prognostic heterogeneity of multiple myeloma (MM) is largely due to different genetic abnormalities. Cytogenetic analysis has revealed that most of MM harbor chromosome aberrations. Amplification of 1q21 is one of the most common chromosomal aberrations. Interphase fluorescence in situ hybridiza...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Wenjun, Guo, Rui, Qu, Xiaoyan, Qiu, Hairong, Li, Jianyong, Zhang, Run, Chen, Lijuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716762/ https://www.ncbi.nlm.nih.gov/pubmed/26834489 http://dx.doi.org/10.2147/OTT.S95381

Ejemplares similares

The independent adverse prognostic significance of 1q21 gain/amplification in newly diagnosed multiple myeloma patients
por: You, Hongying, et al.
Publicado: (2022)

Gain/Amplification of Chromosome Arm 1q21 in Multiple Myeloma
por: Hanamura, Ichiro
Publicado: (2021)

Extramedullary Manifestation in Multiple Myeloma Bears High Incidence of Poor Cytogenetic Aberration and Novel Agents Resistance
por: Qu, Xiaoyan, et al.
Publicado: (2015)

P830: IDENTIFICATION OF NOVEL TARGET GENES CORRELATED WITH 1Q21 AMPLIFICATION IN PATIENTS WITH SMOLDERING MYELOMA AND MULTIPLE MYELOMA
por: Thomas Iannozzi, Nicolas, et al.
Publicado: (2023)

Prognostic Value and Efficacy Evaluation of Novel Drugs for Multiple Myeloma Patients with 1q21 Amplification (Amp1q21) Only: A Systematic Review of Randomized Controlled Trials
por: Chen, Liang, et al.
Publicado: (2020)

1q21 Gain Combined with High‐Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China
por: Li, Xiaozhe, et al.
Publicado: (2019)

Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens
por: Liu, Xiao, et al.
Publicado: (2022)

Chromosome 1q21 abnormalities in multiple myeloma
por: Schmidt, Timothy M., et al.
Publicado: (2021)

Identification of clinical implications and potential prognostic models of chromatin regulator mutations in multiple myeloma
por: Zhang, Lina, et al.
Publicado: (2022)

Multiple Myeloma With Amplification of Chr1q: Therapeutic Opportunity and Challenges
por: Sklavenitis-Pistofidis, Romanos, et al.
Publicado: (2022)

Characteristics and prognostic value of extramedullary chromosomal abnormalities in extramedullary myeloma
por: Xia, Yuan, et al.
Publicado: (2022)

Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma
por: Zhang, Lina, et al.
Publicado: (2021)

Clinical features of multiple myeloma patients with isolated extramedullary relapse
por: Qu, Xiaoyan, et al.
Publicado: (2018)

Adverse outcome associated with daratumumab-based treatments in relapsed/refractory multiple myeloma patients with amplification of chromosome arm 1q21: a single-center retrospective experience
por: Barbieri, Emiliano, et al.
Publicado: (2022)

Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China
por: Gao, Wen, et al.
Publicado: (2020)

The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event
por: Locher, Maurus, et al.
Publicado: (2020)

IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification
por: Teoh, Phaik Ju, et al.
Publicado: (2020)

Argonaute 2 promotes myeloma angiogenesis via microRNA dysregulation
por: Wu, Shuang, et al.
Publicado: (2014)

t(14;18)(q32;q21) in chronic lymphocytic leukemia patients: Report of two cases and a literature review
por: Chen, Weifeng, et al.
Publicado: (2016)

Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real‐world analysis
por: Wang, Yu‐tong, et al.
Publicado: (2022)

Role of 1q21 in Multiple Myeloma: From Pathogenesis to Possible Therapeutic Targets
por: Burroughs Garcìa, Jessica, et al.
Publicado: (2021)

High-risk multiple myeloma predicted by circulating plasma cells and its genetic characteristics
por: Xia, Yuan, et al.
Publicado: (2023)

Amplification of Chromosome 1q Predicts Poor Overall Survival in Newly Diagnosed Multiple Myeloma Patients
por: Skerget, Matevz, et al.
Publicado: (2023)

Adverse Prognostic Impact of Bone Marrow Microvessel Density in Multiple Myeloma
por: Lee, Nuri, et al.
Publicado: (2015)

S185: TARGETING DNA2 OVERCOMES METABOLIC REPROGRAMMING IN 1Q21 MULTIPLE MYELOMA
por: Thongon, Natthakan, et al.
Publicado: (2023)

Evidence for ABL Amplification in Multiple Myeloma and Therapeutic Implications
por: Huang, He, et al.
Publicado: (2022)

The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain
por: Tang, Hoi Ki Karen, et al.
Publicado: (2022)

Identifying 1q amplification and PHF19 expressing high-risk cells associated with relapsed/refractory multiple myeloma
por: Johnson, Travis S., et al.
Publicado: (2023)

Baohuoside I Inhibits Tumor Angiogenesis in Multiple Myeloma via the Peroxisome Proliferator–Activated Receptor γ/Vascular Endothelial Growth Factor Signaling Pathway
por: Chen, Ying, et al.
Publicado: (2022)

Aggressive Clinicopathological Course of Myeloma with t(3;16) (q21;q22) Cytogenetic Abnormality
por: Bozkurt, Süreyya, et al.
Publicado: (2019)

The hydroxymethylome of multiple myeloma identifies FAM72D as a 1q21 marker linked to proliferation
por: Chatonnet, Fabrice, et al.
Publicado: (2020)

Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma
por: Pan, Darren, et al.
Publicado: (2021)

P22 THE PROGNOSTIC ROLE OF 1Q ABNORMALITIES IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
por: Attucci, I., et al.
Publicado: (2023)

Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma
por: He, JingSong, et al.
Publicado: (2021)

Advances in the treatment of extramedullary disease in multiple myeloma
por: Li, Yating, et al.
Publicado: (2022)

Prenatal Diagnosis and Genetic Analysis of 21q21.1–q21.2 Aberrations in Seven Chinese Pedigrees
por: Hu, Huamei, et al.
Publicado: (2021)

Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patients
por: Chen, Xuduan, et al.
Publicado: (2020)

Echocardiography‐defined pulmonary hypertension is an adverse prognostic factor for newly diagnosed multiple myeloma patients
por: Jian, Yuan, et al.
Publicado: (2022)

Anaplastic multiple myeloma with amplification of the IGH-CCND1 gene fusion
por: Alencar, Rafael Nobrega, et al.
Publicado: (2023)

Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma
por: Li, Fei, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_sqhticjkgivsni0d1i5a8gcifj